Edition:
United States

Julie Steenhuysen

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

Aug 03 2018

Eisai/Biogen to advance Alzheimer's drug, provide fresh hope

(In this July 24th story, corrects paragraphs 3 and 16 to clarify that Eisai executive said the trial generated positive, rather than effective, results at lower doses)

Jul 26 2018

Investors turn wary on Biogen/Eisai Alzheimer's drug results

CHICAGO/TOKYO Shares of Eisai Co Ltd plunged as much as 21 percent after the results of its experimental Alzheimer's drug being developed with partner Biogen Inc failed to enthuse investors.

Jul 25 2018

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Jul 25 2018

Lowering blood pressure cuts risk of memory decline: U.S. study

CHICAGO Aggressively lowering blood pressure significantly reduced the risk of mild cognitive impairment and dementia among hypertension patients in a large government-backed clinical trial, U.S. researchers said on Wednesday.

Jul 24 2018

Focus: Eisai/Biogen to advance Alzheimer's drug, provide fresh hope

Eisai Co Ltd and Biogen Inc will move forward with late-stage clinical trials of their Alzheimer’s disease drug, BAN2401, and are working with regulators to design the next studies and gain expedited review as a breakthrough therapy.

Jun 26 2018

Modified polio vaccine extends lives in U.S. brain cancer study

CHICAGO Some 21 percent of patients with advanced brain cancer treated with a modified polio vaccine were alive after three years, compared with 4 percent of patients with similar tumors who received standard therapies, U.S. researchers said on Tuesday. | Video

Jun 13 2018

Study confirms higher risk of dengue in kids who got Sanofi vaccine

CHICAGO An analysis of data on Sanofi's dengue vaccine, which has been given to more than 800,000 school children in the Philippines, confirms it increases the risk of hospitalization and severe dengue in those who had never previously been infected with the mosquito-borne virus.

Jun 09 2018

Rise in U.S. suicides highlights need for new depression drugs

CHICAGO A spike in suicide rates in the United States has cast fresh light on the need for more effective treatments for major depression, with researchers saying it is a tricky development area that has largely been abandoned by big pharmaceutical companies.

Jun 09 2018

Rise in U.S. suicides highlights need for new depression drugs

CHICAGO A spike in suicide rates in the United States has cast fresh light on the need for more effective treatments for major depression, with researchers saying it is a tricky development area that has largely been abandoned by big pharmaceutical companies.

Jun 08 2018

Bourdain, Spade suicides highlight need for new depression drugs

CHICAGO, June 8 The suicides this week of Anthony Bourdain and Kate Spade have cast fresh light on the need for more effective treatments for major depression, an area that has been largely abandoned by big pharmaceutical companies.

Markets

  • U.S.
  • Europe
  • Asia
  • Sectors

Sector Summary